Image Ben Hargreaves R&D Data-driven disease research harnessing the genome Ben Hargreaves speaks to the UK Biobank to learn more about their work building a dataset of 500,000 individuals. R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident. Patients The rapidly evolving role of patient organisations Ben Hargreaves finds that patient organisations are providing an increasingly essential role as a linker between patients and the rest of the life sciences industry. R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Load more results
R&D Data-driven disease research harnessing the genome Ben Hargreaves speaks to the UK Biobank to learn more about their work building a dataset of 500,000 individuals.
R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.
Patients The rapidly evolving role of patient organisations Ben Hargreaves finds that patient organisations are providing an increasingly essential role as a linker between patients and the rest of the life sciences industry.
R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
